Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levocetirizine with or without tranexamic acid for chronic spontaneous urticaria
2018-003139-31Phase 3Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levocetirizine and tranexamic acid in chronic idiopathic urticaria (CIU) (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Change in UAS7 score from baseline to day 28. Started Oct 2018; status: terminated.
02
Drugs
levocetirizinetranexamic acid
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2018-003139-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003139-31.